Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma
the ONA take:
According to results presented at the 20th Congress of the European Hematology Association, researchers have found that patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone if they have received at least two prior treatment regimens, including an immunomodulatory agent and bortezomib.
The subgroup analysis, which included 147 patients, demonstrated a 12.5-month progression-free survival for patients who had received at least 2 prior regimens and received panobinostat compared with a progression-free survival of 4.7 months with placebo.
The overall study showed a 3.9-month improvement in median progression-free survival with panobinostat versus placebo.
"Together, these data identify the subgroup of patients with relapsed or relapsed and refractory [multiple myeloma] who benefits most with panobinostat-bortezomib-dexamethasone," Dr. Hermann Einsele, director of the Medical Clinic at University of Wurzberg in Germany said. "The findings support the recent [Food and Drug Administration] approval of the panobinostat combination in [multiple myeloma] patients who received ≥2 prior regimens, including IMiDs and bortezomib."
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|